[go: up one dir, main page]

BRPI0812535A2 - derivado de 17beta-ciano-19-androst-4-eno, seu uso e medicamentos compreendendo o derivado - Google Patents

derivado de 17beta-ciano-19-androst-4-eno, seu uso e medicamentos compreendendo o derivado

Info

Publication number
BRPI0812535A2
BRPI0812535A2 BRPI0812535A BRPI0812535A BRPI0812535A2 BR PI0812535 A2 BRPI0812535 A2 BR PI0812535A2 BR PI0812535 A BRPI0812535 A BR PI0812535A BR PI0812535 A BRPI0812535 A BR PI0812535A BR PI0812535 A2 BRPI0812535 A2 BR PI0812535A2
Authority
BR
Brazil
Prior art keywords
derivative
17beta
androst
medicaments
cyano
Prior art date
Application number
BRPI0812535A
Other languages
English (en)
Inventor
Menges Frederik
Muhn Hans-Peter
Huebner Jan
Kuhnke Joachim
Prelle Katja
Bohlmann Rolf
Borden Steffen
Ring Sven
Franzel Thomas
Klar Ulrich
Original Assignee
Bayer Schering Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Schering Pharma Ag filed Critical Bayer Schering Pharma Ag
Publication of BRPI0812535A2 publication Critical patent/BRPI0812535A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0094—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 containing nitrile radicals, including thiocyanide radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/34—Gestagens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J53/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by condensation with a carbocyclic rings or by formation of an additional ring by means of a direct link between two ring carbon atoms, including carboxyclic rings fused to the cyclopenta(a)hydrophenanthrene skeleton are included in this class
    • C07J53/002—Carbocyclic rings fused
    • C07J53/004—3 membered carbocyclic rings
    • C07J53/007—3 membered carbocyclic rings in position 6-7
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J53/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by condensation with a carbocyclic rings or by formation of an additional ring by means of a direct link between two ring carbon atoms, including carboxyclic rings fused to the cyclopenta(a)hydrophenanthrene skeleton are included in this class
    • C07J53/002—Carbocyclic rings fused
    • C07J53/004—3 membered carbocyclic rings
    • C07J53/008—3 membered carbocyclic rings in position 15/16

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Gynecology & Obstetrics (AREA)
  • Toxicology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BRPI0812535A 2007-06-12 2008-06-12 derivado de 17beta-ciano-19-androst-4-eno, seu uso e medicamentos compreendendo o derivado BRPI0812535A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE102007027635A DE102007027635A1 (de) 2007-06-12 2007-06-12 17ß-Cyano-19-androst-4-en-Derivat, dessen Verwendung und das Derivat enthaltende Arzneimittel
US94365107P 2007-06-13 2007-06-13
PCT/EP2008/057427 WO2008152112A2 (de) 2007-06-12 2008-06-12 17ß-CYANO-19-ANDROST-4-EN-DERIVAT, DESSEN VERWENDUNG UND DAS DERIVAT ENTHALTENDE ARZNEIMITTEL

Publications (1)

Publication Number Publication Date
BRPI0812535A2 true BRPI0812535A2 (pt) 2017-05-16

Family

ID=39986162

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0812535A BRPI0812535A2 (pt) 2007-06-12 2008-06-12 derivado de 17beta-ciano-19-androst-4-eno, seu uso e medicamentos compreendendo o derivado

Country Status (15)

Country Link
US (1) US20100292184A1 (pt)
EP (1) EP2167525A2 (pt)
JP (1) JP2010529174A (pt)
KR (1) KR20100037596A (pt)
CN (1) CN101679479A (pt)
AU (1) AU2008263857A1 (pt)
BR (1) BRPI0812535A2 (pt)
CA (1) CA2692997A1 (pt)
CL (1) CL2008001720A1 (pt)
DE (1) DE102007027635A1 (pt)
IL (1) IL202325A0 (pt)
MX (1) MX2009013631A (pt)
RU (1) RU2010100337A (pt)
WO (1) WO2008152112A2 (pt)
ZA (1) ZA201000186B (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010066349A1 (de) * 2008-12-12 2010-06-17 Bayer Schering Pharma Aktiengesellschaft Verwendung von 17beta-cyano-19-androst-4-en-derivaten zur herstellung eines arzneimittels in depot-form zur parenteralen anwendung sowie depot-arzneimittel enthaltend 17beta-cyano-19-androst-4-en-derivate zur parenteralen anwendung
WO2012059594A1 (en) 2010-11-04 2012-05-10 Bayer Pharma Aktiengesellschaft Mineralcorticoid receptor antagonists for the treatment of corticoid-induced obesity
CN105085596A (zh) * 2015-08-18 2015-11-25 湖北竹溪人福药业有限责任公司 一种羧酸黄体酮的制备方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1183500B (de) 1962-10-12 1964-12-17 Schering Ag Verfahren zur Herstellung von alpha, beta-Methylenketonen der Steroidreihe
GB1089945A (en) * 1965-09-23 1967-11-08 British Drug Houses Ltd Steroidal-6-spirocyclopropyl-4-en-3-ones
DE1593516C3 (de) * 1966-08-25 1975-05-15 Schering Ag, 1000 Berlin Und 4619 Bergkamen 4-Halogen-1,2 alpha; 6,7 betabismethylen-delta hoch 4-3-ketosteroide, Verfahren zu ihrer Herstellung sowie diese Steroide enthaltende Mittel
DE2109555C3 (de) 1971-02-24 1980-10-30 Schering Ag Neue 15 a , 16 a -Methylensteroide, diese enthaltende Arzneimittel sowie Verfahren zu ihrei Herstellung
US3705179A (en) 1971-03-15 1972-12-05 American Home Prod Antiandrogenic steroids
FR2139708B1 (pt) * 1971-06-01 1974-08-23 Roussel Uclaf
NL7701384A (nl) 1977-02-10 1978-08-14 Akzo Nv Werkwijze voor het bereiden van nieuwe steroiden van de oestraanreeks.
DE2922500A1 (de) 1979-05-31 1980-12-04 Schering Ag 6 beta .7 beta
US4512986A (en) * 1983-07-26 1985-04-23 Research Triangle Institute Progrestationally active steroids
DE3402329A1 (de) 1984-01-20 1985-08-01 Schering AG, 1000 Berlin und 4709 Bergkamen 6,6-ethylen-15,16-methylen-3-oxo-17(alpha)-pregn-4-en-21,17-carbolactone, verfahren zu deren herstellung und diese enthaltende pharmazeutische praeparate
HU204063B (en) * 1986-10-10 1991-11-28 Gist Brocades Nv Process for producing 9-alpha-hydroxy steroids
DE19651000A1 (de) 1996-12-01 1998-06-04 Schering Ag Oxyiminopregnancarbolactone
EP1359154A1 (en) * 2002-04-29 2003-11-05 BOEHRINGER INGELHEIM INTERNATIONAL GmbH Further syntheses of cyproterone acetate
ITMI20042338A1 (it) * 2004-12-06 2005-03-06 Ind Chimica Srl Processo per la preparazione di drospirenone
DE102004063864A1 (de) * 2004-12-30 2006-07-13 Schering Ag 18-Methyl-19-nor-17-pregn-4-en21,17-carbolactone, sowie diese enthaltende pharmazeutische Präparate
DE102007027637A1 (de) * 2007-06-12 2008-12-18 Bayer Schering Pharma Aktiengesellschaft 17ß-Cyano-19-nor-androst-4-en-Derivat, dessen Verwendung und das Derivat enthaltende Arzneimittel

Also Published As

Publication number Publication date
CN101679479A (zh) 2010-03-24
RU2010100337A (ru) 2011-07-20
WO2008152112A2 (de) 2008-12-18
CA2692997A1 (en) 2008-12-18
IL202325A0 (en) 2010-06-30
MX2009013631A (es) 2010-01-20
CL2008001720A1 (es) 2008-12-19
JP2010529174A (ja) 2010-08-26
ZA201000186B (en) 2011-03-30
US20100292184A1 (en) 2010-11-18
WO2008152112A3 (de) 2009-04-30
DE102007027635A1 (de) 2008-12-18
KR20100037596A (ko) 2010-04-09
EP2167525A2 (de) 2010-03-31
AU2008263857A1 (en) 2008-12-18

Similar Documents

Publication Publication Date Title
BRPI0813455A2 (pt) Derivado de 17beta-ciano-18a-homo-19-nor-androst-4-eno, seu uso e medicamentos contendo este derivado.
BRPI0808098A2 (pt) 4-aril-1,4-di-hidro-1,6-naftiridinamidas substituídas e seu uso
BRPI0814267A2 (pt) Agentes citotóxicos compreendendo novos derivados de tomaicmicina e o seu uso terapêutico.
BRPI0821276A2 (pt) Produto, e, uso do produto
BRPI0718182A2 (pt) Oligorribonucleotídeos e seus usos.
BRPI0815190A2 (pt) Composto derivado de piridina, composição farmacêutica que o compreende e uso do mesmo
BRPI0618904A2 (pt) composto, composição farmacêutica, e, uso do composto
EP1933936A4 (en) IMPREGNATED ENVELOPE OF MEDICAMENT
BRPI0821668A2 (pt) Uso
BRPI0614205A2 (pt) composto, composição farmacêutica, e, uso de composto
BRPI0811865A2 (pt) Derivados heterocíclicos pirrolo-nitrogenados, a preparação e o uso farmacêutico dos mesmos
BRPI0815773A2 (pt) composto, e, medicamento.
BRPI0922435A2 (pt) "composto de tiazolopiridina moduladores de sirtuina, composição farmacêutica compreendendo o mesmo e seu uso."
BRPI0813244A2 (pt) Compostos e seus usos 708
BR112012004335A2 (pt) composto, composição farmacêutica, e, uso do composto.
BRPI0808798A2 (pt) Fenoxifenilamidinas 3,5-dissubstituídas e seu uso como fungicidas
BRPI0810654A2 (pt) Tiadiazoliloxifenilamidinas e o seu uso como fungicidas.
BRPI0718192A2 (pt) Corantes dispersos, sua preparação e seu uso.
BRPI0807078A2 (pt) Composto, e, formulação farmacêutica
BRPI0719345A2 (pt) Di-hidroimidazóis substituídos e seu uso no tratamento de tumores.
BRPI0813263A2 (pt) Oxazolidinonas substituídas e seu uso
BRPI0816372A2 (pt) Ácidos 6-fenilnicotínicos substituídos e seu uso
BRPI0818641A2 (pt) Rótulo, e, uso do rótulo
BRPI0808846A2 (pt) fenoxifenilamidinas 3-substituídas e seu uso como fungicidas
BRPI0813587A2 (pt) Composto, uso do mesmo, e, composição farmacêutica

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]